News | December 26, 2023
BioVaxys executes LoI for major Immunotherapeutics technology acquisition
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Furthering cell therapy ambition across oncology and autoimmune diseases
US FDA approval based on NEURO-TTRansform Phase III results
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
The plant is yet to start commercial operations
World HRD Congress is a well-known international body of Management Studies
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Subscribe To Our Newsletter & Stay Updated
